Identification of covariates influencing B-cell repopulation kinetics after Rituximab treatment

Identification of covariates influencing B-cell repopulation kinetics after Rituximab treatment - RTX

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030167

Enrollment

1500

Registered

2022-09-01

Start date

2022-08-23

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B cell repopulation following Rituximab therapy.

Interventions

Group 1: Non-oncological patients receiving Rituximab therapy.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Non-oncological patients receiving Rituximab therapy.

Exclusion criteria

Exclusion criteria: Age < 18 years

Design outcomes

Primary

Measure	Time frame
Time to repopulation of CD19-positive B-lymphocytes (cut-off: = 10 cells/µl), in patient groups stratified by Rituximab dose, Rituximab cycle, age, sex, weight, kidney function, underlying disease, immunosuppressiove co-medication.	—

Secondary

Measure	Time frame
Time to reconstitution of CD19-positive B-lymphocytes (cut-off: = 50 cells/µl), in patient groups stratified by Rituximab dose, Rituximab cycle, age, sex, weight, kidney function, underlying disease, immunosuppressiove co-medication.	—

Countries

Germany

Contacts

Public ContactThomas Welte

Universitätsklinikum Freiburg, Medizinische Klinik IV

thomas.welte@uniklinik-freiburg.de0049-761-270-33470

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026